Bravo Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 12.00 Cr
as on 05-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 05-12-2024
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.37 Cr
as on 05-12-2024
- Revenue -89.23%
(FY 2023)
- Profit -3507.63%
(FY 2023)
- Ebitda 88.50%
(FY 2023)
- Net Worth -1.75%
(FY 2023)
- Total Assets 23.58%
(FY 2023)
About Bravo Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 12.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹18.37 Cr.
Rakesh Pandey, Reena Singh, and Shreekant Panday serve as directors at the Company.
- CIN/LLPIN
U33110DL2011PTC220862
- Company No.
220862
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2011
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Bravo Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Pandey  | Director | 14-Jun-2011 | Current |
| Reena Singh | Director | 24-Jun-2012 | Current |
| Shreekant Panday | Additional Director | 02-Sep-2022 | Current |
Financial Performance of Bravo Pharmaceuticals.
Bravo Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 89.23% decrease. The company also saw a substantial fall in profitability, with a 3507.63% decrease in profit. The company's net worth dipped by a decrease of 1.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bravo Pharmaceuticals?
In 2023, Bravo Pharmaceuticals had a public holding of 24.66%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bravo Ethanol Private LimitedActive 2 years 5 monthsRakesh Pandey and Reena Singh are mutual person
- Bravo Research Lab Private LimitedActive 2 years 5 months
Rakesh Pandey and Reena Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Feb 2024 | ₹2.00 Cr | Open |
Others Creation Date: 23 Aug 2023 | ₹14.49 Cr | Open |
Others Creation Date: 23 Aug 2023 | ₹1.88 Cr | Open |
How Many Employees Work at Bravo Pharmaceuticals?
Unlock and access historical data on people associated with Bravo Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bravo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bravo Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
